Daily Stock Analysis, INDA, INCYTE CORP, priceseries

INCYTE CORP. Daily Stock Analysis
Stock Information
Open
41.24
Close
40.99
High
41.30
Low
40.97
Previous Close
41.80
Daily Price Gain
-0.81
YTD High
42.02
YTD High Date
Jan 13, 2021
YTD Low
40.31
YTD Low Date
Jan 4, 2021
YTD Price Change
0.68
YTD Gain
1.69%
52 Week High
42.02
52 Week High Date
Jan 13, 2021
52 Week Low
20.41
52 Week Low Date
Mar 23, 2020
52 Week Price Change
5.17
52 Week Gain
14.42%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 6. 2020
23.59
Apr 21. 2020
24.92
10 Trading Days
5.66%
Link
LONG
Jul 1. 2020
29.65
Jul 31. 2020
31.86
21 Trading Days
7.47%
Link
LONG
Nov 4. 2020
34.81
Nov 30. 2020
36.59
17 Trading Days
5.12%
Link
Company Information
Stock Symbol
INDA
Exchange
NASDAQ
Company URL
http://www.incyte.com
Company Phone
3024986700
CEO
Hervé Hoppenot
Headquarters
Delaware
Business Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE 19803
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000879169
About

Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. Its product, Jakafi, a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. The companywas founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Description

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The company's clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the company's clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.